James P Flynn
CIK 1955965 · last filed 2026-06-25
James P Flynn is a corporate insider who has filed 13 SEC Form 4 insider transactions across 4 companies since 2022. The most recent filing shows the insider bought $21.4K of LITS on Jun 25, 2026. Across all open-market trades the lifetime net is +$141.9K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $140.0K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
LITS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
DANVILLE, CA 94526
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LITS | Director | 125,000 | $1.12 | $140.0K | $141.9K | 5 | 2026-06-25 |
| Lite Strategy, Inc. (MEIP) Delisted | Director | 7,900 | $3.20 | $25.3K | $0 | 4 | 2025-07-17 |
| SYNLOGIC, INC. (SYBX) Delisted | Director | 15,000 | $0.69 | $10.3K | $0 | 2 | 2025-04-29 |
| Oruka Therapeutics, Inc. (ABIO) Delisted | Director | — | $28.80 | — | $0 | 2 | 2024-01-31 |
Recent Filings
13 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-25 | LITS | Buy (P) | +25,000 | $21.4K | EDGAR |
| 2025-12-22 | LITS | Buy (P) | +70,000 | $97.7K | EDGAR |
| 2025-11-20 | LITS | Buy (P) | +12,100 | $22.8K | EDGAR |
| 2025-11-18 | LITS | Grant (A) | — | $0 | EDGAR |
| 2025-10-02 | LITS | Grant (A) | +10,000 | $25.4K | EDGAR |
| 2025-07-17 | Lite Strategy, Inc. (MEIP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-04-29 | SYNLOGIC, INC. (SYBX) Delisted | Grant (A) | +15,000 | $0 | EDGAR |
| 2024-05-20 | Lite Strategy, Inc. (MEIP) Delisted | Grant (A) | +7,900 | $25.0K | EDGAR |
| 2024-03-21 | SYNLOGIC, INC. (SYBX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-01-31 | Oruka Therapeutics, Inc. (ABIO) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.